A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC).
A. X. Zhu
Consultant or Advisory Role - Novartis; Pfizer; Sanofi
Research Funding - Bayer
P. J. Gold
No relevant relationships to disclose
A. B. El-Khoueiry
Honoraria - AstraZeneca
Research Funding - Abraxis BioScience; AstraZeneca
T. A. Abrams
No relevant relationships to disclose
H. Morikawa
Employment or Leadership Position - Chugai Pharma
Stock Ownership - Chugai Pharma
T. Ohtomo
Employment or Leadership Position - Chugai Pharma
P. A. Philip
Honoraria - Amgen; Bayer; Sanofi
Research Funding - Chugai Pharma; Lilly; Novartis